-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Program: Oral and Poster Abstracts
Type: Poster
Monday, December 11, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Jan S. Rosenbaum, PhD1, Amal S. Kolt, MS1*, Scott B. Hoyt, PhD2*, Gregory M. Hayes, PhD1*, Brandi L. Soldo, PhD1*, Craig J. Thomas, PhD3* and Daniel T. Starczynowski, PhD4

1Kurome Therapeutics Inc., Cincinnati, OH
2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
3Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
4Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Chia Sharpe, PhD1, Sara Elgamal, PhD1, Sydney Fobare, PhD2, Casie Furby1*, Marissa Long1*, Kinsey Bryant1*, Carolyn Cheney, BS1*, James R. Lerma1*, Megan E. Johnstone, PhD1*, Andrew Orry, PhD3*, Polo Chun-Hung Lam, PhD3*, Ruben Abagyan, PhD3*, Volodymyr Kysil, PhD4*, Hovhannes Gukasyan, PhD4*, Oleg Mitkin, PhD4*, Ruben Karapetian, PhD4*, Alexey Ryakhovskiy, PhD4*, Elena Bulanova, PhD4*, Vladislav Parchinsky, PhD4*, Alexandre Ivachtchenko, PhD4*, Kate Dokukina, MD, PhD5*, Alexei Pushechnikov, PhD4*, Nikolay Savchuk, PhD5*, Iain Dukes, DPhil5*, Amy Burd, PhD5, Erin K. Hertlein, PhD1 and John C. Byrd, MD1

1Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
2Medical Scientist Training Program, The Ohio State University, Columbus, OH
3MolSoft LLC, San Diego, CA
4ChemDiv Inc, San Diego, CA
5Eilean Therapeutics, Philadelphia, PA

Zhe WANG, MD1*, Qi Zhang, PhD1*, Anna Skwarska2*, Cassandra L. Ramage1*, Guangrong Zheng3*, Kira Gritsman, MD, PhD4, Kapil N. Bhalla, MD1, Naveen Pemmaraju, MD1, Daohong Zhou, MD5*, Jeffrey W Tyner, PhD6 and Marina Y. Konopleva1,2

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
3Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL
4Department of Medical Oncology, Montefiore Medical Center, Bronx, NY
5Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX
6Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Anna Skwarska, PhD1*, Vinitha Mary Kuruvilla, MSc2*, Qi Zhang, PhD2*, Sovira Chaudhry, MSc1*, Naval Daver, MD2, Krystal Watkins3*, Callum Mortimer Sloss, PhD3*, Patrick A. Zweidler-McKay, MD, PhD3, Deepa Sampath, PhD4 and Marina Y. Konopleva, MD, PhD1,2*

1Cancer Center, Albert Einstein College of Medicine, New York, NY
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3ImmunoGen, Inc., Waltham, MA
4Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

Kanwaldeep Singh, PhD1,2*, Emily Hartung, MSc1,2*, Christina Muhs3,4,5,6*, Islam Alshamleh, PhD3,4,5,6*, Monisha Divakaran1,2*, Anna Dvorkin-Gheva7*, Sara Pishyar, MSc1,2*, Pradhariny Prabagaran, MSc1,2*, Dina Khalaf, MSc, MBBS2,8, Alejandro Garcia-Horton, MD2,8, Stephen Ronan Foley, MD2,8*, Brian Leber, MD8,9, Irwin Walker, MBBS8,9, Kylie Lepic, MD2,8*, Harald Schwalbe, Prof. PhD3,4,5*, Hubert Serve, MD4,5,6*, Maria Kleppe, PhD, RPh10*, Hugh Young Rienhoff Jr., MD10 and Tobias Berg, MD1,2,11

1Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada
2Department of Oncology, McMaster University, Hamilton, ON, Canada
3Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe University Frankfurt, Frankfurt, Germany
4German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany
5Department of Medicine, Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany
6Frankfurt Cancer Institute, Johann Wolfgang Goethe University, Frankfurt, Germany
7Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada
8Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
9Department of Medicine, McMaster University, Hamilton, ON, Canada
10Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ
11Escarpment Cancer Research Institute, Hamilton Health Sciences / McMaster University, Hamilton, ON, Canada

Leonie Elisabeth Kampa1*, Anton Bleisch2*, Philipp Peslalz2*, Marcus Matthias Schittenhelm, MD3*, Bernd Plietker2* and Kerstin Maria Kampa-Schittenhelm, MD1,4

1Medical Oncology and Hematology and Medical Research Facility (MFZ), Kantonsspital St. Gallen, St. Gallen, Switzerland
2Technical University of Dresden, Dresden, Germany
3Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
4Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, University Hospital Tuebingen, Tubingen, Germany

Bing Z. Carter, PhD1, Po Yee Mak1*, Baozhen Ke1*, Andrea Bedoy1*, Steffen Boettcher, MD2*, Lauren B. Ostermann, BSc1*, Elizabeth J. Shpall, MD3 and Michael Andreeff, MD PhD4

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2University Hospital Zurich, Zurich, Zurich, Switzerland
3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Abdullah Khasawneh1*, Faith Jessica Paran, PhD2*, Rieko Oyama2*, Abhishek Maiti, MD3, Hussein A Abbas, MD, PhD3,4, Bofei Wang, Ph.D.3*, Poonam N Desai3, Kala Hayes, PhD3*, Joe R Harman, PhD5*, Xiaoping Su, PhD6*, Courtney D. DiNardo, MD, MSc3, Michael Andreeff, MD PhD3, Thomas A Milne, PhD5*, Marina Y. Konopleva3,7 and Yoko Tabe, MD, PhD2,3,8*

1Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo, Japan
2Department of Research Support Utilizing Bioresource Bank, Juntendo University Graduate School of Medicine, Tokyo, Japan
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
5MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
6Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
8Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Warren C. Fiskus, BSc, PhD1, Jessica Piel, PhD, BA2*, Murphy Hentemann2*, Christopher Peter Mill, PhD, BA3, Christine Birdwell, PhD3, Kaberi Das1*, John Davis3*, Hanxi Hou4*, Noor Alhamadani4*, Kevin Philip4*, Alicia Matthews4*, Tapan M. Kadia, MD5, Naval Daver, MD5, Sanam Loghavi, MD6, Branko Cuglievan4, Courtney D. DiNardo, MD, MSc5 and Kapil N. Bhalla, MD5

1UT MD Anderson Cancer Center, Houston, TX
2Foghorn Therapeutics Inc., Cambridge, MA
3MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Hematopathology, MD Anderson Cancer Center, Houston, TX

Xubo Gong1,2*, Yi Zhang2,3*, Ying-Chieh Chen, PhD2*, Dandan Zhao2*, Yongfang Xu2*, Xin He, MD2*, Fang Chen2*, Lei Zhang, MD2*, Lianjun Zhang, PhD2*, Katrina Estrella2*, Melissa Valerio2*, Lucy Y. Ghoda, PhD2*, Le Xuan Truong Nguyen, PhD2*, Ya-Huei Kuo, PhD2, Weiwei Liu1*, Zhihua Tao1*, Guido Marcucci, MD2 and Bin Zhang2*

1Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA
3Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;, Hangzhou, China

Kotoko Yamatani, MD1*, Tatsuro Watanabe, PhD2*, Kaori Saito1*, Abhishek Maiti, MD3, Satoshi Yamashita, PhD4*, Abdullah Khasawneh1*, Faith Jessica Paran, PhD5*, Kala Hayes, PhD6*, Gautam Borthakur, MD6, Joe R Harman, PhD7*, Shinya Kimura, MD, PhD8, Courtney D. DiNardo, MD, MSc6, Thomas A Milne, PhD7*, Michael Andreeff, MD PhD6, Yoko Tabe, MD, PhD1,6* and Marina Y. Konopleva6,9

1Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4Department of Life Engineering, Faculty of Engineering, Maebashi Institute of Technology, Gunma, Japan
5Department of Research Support Utilizing Bioresource Bank, Juntendo University Graduate School of Medicine, Tokyo, Japan
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
8Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Saga, Japan
9Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

Yin Yuan, MBBS1,2,3, Sarah T Diepstraten, PhD1,2*, Fiona C. Brown, PhD1,2*, Veronique Litalien1,2*, Andreas Strasser, PhD, MSc1,2*, Gemma L Kelly, PhD1,2*, Andrew W. Roberts, MBBS, PhD1,2,3 and Andrew H. Wei, MBBS, PhD1,2,3

1The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
2The University of Melbourne, Melbourne, Australia
3Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Moran Wang, PhD1*, Wei Shi, PhD1*, Ruiqi Zhu, PhD1*, Donald Small, MD, PhD2, Li Li, MD3*, Shengling Ma, MD4 and Yu Hu, MD1*

1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
3Johns Hopkins Univ. School of Med., Baltimore, MD
4Section of Hematology-Oncology, Baylor College of Medicine, HOUSTON, TX

Irene Zacheo1*, Anna Ferrari1*, Eugenio Fonzi2*, Maria Teresa Bochicchio3*, Giorgia Capirossi4*, Jacopo Nanni, MD5*, Matteo Paganelli4*, Chiara Servilli4*, Lorenzo Ledda4*, Martina Ghetti, MSc3*, Mouna Jandoubi4*, Matteo Marchesini1*, Agnese Mattei1*, Giovanni Martinelli, MD6, Giovanni Marconi, MD4 and Giorgia Simonetti, PhD3*

1Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy
2IRST IRCSS, Meldola (FC), ITA
3IRCSS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l, Meldola, Italy
4Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Italy
5Department of Medical and Surgical Sciences, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy
6IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST S.r.l., Meldola, Italy

Leila Mahdavi1*, Haley Goodrow2*, Hongbo Xie1*, Alexandra Lenard1*, Fatemeh Alikarami, PhD2*, Simone Stefanie Riedel, PhD2, Sarah K Tasian, MD1, Gerald Wertheim, MD, PhD3*, Sarah Skuli, MD, PhD4, Martin Carroll, MD5, Jerry McGeehan, PhD6* and Kathrin M. Bernt, MD1

1Children's Hospital of Philadelphia, Philadelphia, PA
2The Children's Hospital of Philadelphia, Philadelphia, PA
3Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA
4University of Pennsylvania, Philadelphia, PA
5Division of Hematology/Oncology, Department of Medicine, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA
6Syndax, Waltham, MA

Min Chul Kwon1, Tinne Verhulst1*, Dries Goffin1*, Ann Marien1*, Bie Verbist, PhD1*, Christina Guttke, PhD2*, Jan Willem Thuring, PhD1*, Lucille Ferrante, MD, MS2, Nikki Daskalakis, MD2*, E. Christine Pietsch, PhD3, Yusri Elsayed, MD, MMSc, PhD2, Kathryn Packman, PhD4* and Ulrike Philippar, PhD1

1Janssen Research & Development, LLC, Beerse, Belgium
2Janssen Research & Development, LLC, Spring House, PA
3Janssen Research and Development, Springhouse, PA
4Janssen Research & Development, LLC, Cambridge, MA

Md. Hafiz Uddin1*, Amro Aboukameel1*, Sharif hasan Siddiqui, Ph.D.1*, Husain Khan1*, Sahar Bannoura2*, Abhinav Deol, MD1*, Jay Yang, MD1, Gregory Dyson, PhD3*, Asfar Azmi1*, Lisa Polin1*, Jaroslaw P. Maciejewski, M.D., Ph.D., FACP4 and Suresh Kumar Balasubramanian, MD3,4

1Karmanos Cancer Institute/ Department of Oncology, Wayne State University, Detroit, MI
2Karmanos Cancer Institute/ Department of Oncology, Detroit, MI
3Karmanos Cancer Institute/Department of Oncology, Wayne State University, Detroit, MI
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Valerio Ciaurro, Ph.D1*, Marina Y. Konopleva2,3, Naval Daver, MD3, Anna Skwarska2* and Maria Paola Martelli, MD, PhD4*

1MD anderson Cancer center, HOUSTON, TX
2Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Dipartimento di Medicina e Chirurgia, Hematology, Department of Medicine and Surgey, University of Perugia and "Santa Maria della Misericordia" Hospital, Perugia, ITA

Kellen Gil, MD, MPH1, Jamie Borg, BS2*, Anagha Inguva Sheth, BSc3, Rosana Pereira, MS3*, Jeremy Rahkola, BS2* and Maria L Amaya, MD, PhD2,4

1Internal Medicine Residency, University of Colorado School of Medicine, Aurora, CO
2Rocky Mountain Regional VA Medical Center, Aurora, CO
3University of Colorado, Aurora, CO
4Division of Hematology, University of Colorado, Aurora, CO

Cheryl A C Peretz, MD1, Elaine Tran2*, Bogdan Popescu, MD3*, Vanessa E. Kennedy, MD3, Tanya Kumar1*, Lisa McGary4*, Natalie Tantisira2*, Eric Wong2*, Jose M. Rivera5*, Simayijiang Xirenayi6*, Elliot Stieglitz, MD5, Catherine C. Smith, MD3 and Juwita Hübner, MD5*

1UCSF, San Francisco, CA
2UCSF, San Francisco
3Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
4University of California San Francisco, San Francisco, CA
5Department of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA
6University California San Francisco, San Francisco, CA

Anya L Levinson, MD1, Karensa Tjoa2*, Benjamin J Huang, MD1, Nicolas Bland2*, Steven P. Angus, PhD3*, CHI Zhang, PhD4*, Luca Gerosa5*, Darlene Dela Cruz6*, Udi Segal6*, Scott Foster7* and Kevin Shannon, MD1*

1Department of Pediatrics, University of California, San Francisco, San Francisco, CA
2University of California, San Francisco, San Francisco, CA
3Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis
4Department of Pediatrics, Department of Medical and Molecular Genetics, Indiana University, Indianapolis
5Department of Oncology Bioinformatics, Genentech, Inc, South San Francisco
6Department of Translational Oncology, Genentech, Inc., South San Francisco
7Department of Discovery Oncology, Genentech, Inc., South San Francisco

Timothy T. Ferng, MD1*, Samantha M. Pintar, BA2*, Vanessa E. Kennedy, MD2, Theodore C. Tarver III, BS2*, Shaheen Kabir, PhD1*, Veronica Steri, PhD3*, Juan Antonio Camara Serrano, PhD3*, Fernando Salangsang3*, Paul Phojanakong, BA3*, Juwita Hübner, MD4*, Carolina E. Morales, BS4*, Jose M. Rivera4*, Aaron C. Logan, MD, PhD1, Benjamin Braun, MD, PhD4*, Elliot Stieglitz, MD4, Luke A. Gilbert, PhD1* and Catherine C. Smith, MD2

1Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
2Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA
3Preclinical Therapeutics Core, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
4Department of Pediatrics, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA

Fanny Gonzales, MD, PhD1,2, Shan Lin, PhD1,2*, Delan Khalid1,2*, Jana M Ellegast, MD1,2, Gabriela Alexe, PhD1,3* and Kimberly Stegmaier, MD4,5

1The Broad Institute of MIT and Harvard, Cambridge, MA
2Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Boston, MA
3Pediatric Oncology, Dana-Farber Cancer Institute, Boston
4Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
5The Broad Institute of MIT and Harvard, Cambridge

Milena Mazan, PhD1*, Urszula Pakulska, PhD2*, Adrianna Moszyńska, PhD2*, Agnieszka Sroka-Porada2*, Krzysztof Tomasz Szade, PhD3*, Michał Mikula, PhD4*, Magdalena Kozakowska, PhD2*, Przemysław Juszczyński, MD, PhD5*, Katarzyna Wiklik, PhD2*, Kristina Göller, BSc2*, Marta Obacz, MSc2*, Camille N. Abboud, MD6, Jan Maciej Zaucha, Prof7*, Ewa Lech Marańda, Prof8*, Noemi Angelosanto, MD2, Hendrik Nogai, MD2* and Tomasz Rzymski, PhD2*

1Ryvu Therapeutics, Krakow, AL, Poland
2Ryvu Therapeutics, Kraków, Poland
3Jagiellonian University, Kraków, Poland
4Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
5Institute of Hematology and Transfusion Medicine, Warsaw, Poland
6Washington University School of Medicine, Saint Louis, MO
7Department of Haematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
8Institute of Hematology and Transfusion Medicine, Warszawa, Poland

Anna Sergeeva, PhD1*, Hong He, MD, PhD1*, Lisa St. John, PhD1*, Ling Yu1*, Rong Cai1*, Kathryn Ruissard2*, Karen Clise-Dwyer, PhD2*, Rolando Vedia, MS1*, Dan Li1*, Qing Ma, PhD1*, Celine Kerros, PhD3*, Mithil Chokshi, Ph.D.4*, Vanshika Jhonsa4*, Gang Bao, PhD4*, Gheath Alatrash, PhD, DO1 and Jeffrey J. Molldrem, MD5

1Department of Hematopoietic Biology and Malignancy, University of Texas M. D. Anderson Cancer Center, Houston, TX
2Flow Cytometry Core Facility, University of Texas M. D. Anderson Cancer Center, Houston, TX
3ECLIPSE, Therapeutics Discovery and Development, University of Texas M. D. Anderson Cancer Center, Houston, TX
4Department of Bioengineering, Rice University, Houston, TX
5Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

Gene Li, PhD*, Zhongde Ye, PhD*, Poonam Yakkundi, PhD*, Marigold Manlusoc*, Kathryn Logronio*, Leyla Tahrani, PhD*, Rodnie Rosete*, David Bernados*, Paul Hinton*, Deepal Pandya*, Nardeen Hanna*, Jey Anantam, PhD*, Maya F Kotturi, PhD*, Liz Bogaert, PhD*, Jiyoung Hong, PhD*, Christina Tsai, PhD*, Thomas Manley, MD, Bruce A Keyt, PhD, Angus M. Sinclair, PhD and Liqin Liu, PhD*

IGM Biosciences, Inc., Mountain View, CA

Aintzane Zabaleta1*, Esperanza Martín-Sánchez1*, Laura Blanco1*, Peter Kim2*, Kamlesh Bisht, PhD2*, Hongfang Wang, PhD2*, Helgi J. Van de Velde, MD, PhD2, Tomas Jelinek, MD, PhD3,4,5, Catia Simoes, PhD1*, Felipe Prosper, MD, PhD6, Jesus San-Miguel, MD, PhD1, David Martinez-Cuadron, PhD7*, Pau Montesinos, PhD, MD8* and Bruno Paiva6*

1CIMA (Pamplona)Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain
2Sanofi R&D, North America, Cambridge, MA
3Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, Ostrava, Ostrava-Mesto, Czech Republic
4Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain
5Faculty of Science, University of Ostrava, Ostrava, Czech Republic
6Cancer Center Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain
7Hospital Universitario y Politécnico La Fe, Valencia, Spain
8Hospital Universitari i Politecnic la Fe, Valencia, Spain

*signifies non-member of ASH